Xeloda News and Research

RSS
Xeloda is a drug used to treat stage III colon cancer in patients who had surgery to remove the cancer. It is also used to treat metastatic breast cancer that has not improved after treatment with certain other anticancer drugs. Xeloda is being studied in the treatment of other types of cancer. It is taken up by cancer cells and breaks down into 5-fluorouracil, a substance that kills tumor cells. Xeloda is a type of antimetabolite. Also called capecitabine.
Treatment combination improves survival in advanced HER2-positive breast cancer patients

Treatment combination improves survival in advanced HER2-positive breast cancer patients

Drug combination lengthens lives of metastatic colorectal cancer patients

Drug combination lengthens lives of metastatic colorectal cancer patients

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Teva launches generic Xeloda Tablets in the U.S.

Teva launches generic Xeloda Tablets in the U.S.

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

Results from Roche's trastuzumab emtansine Phase III trial on HER2-positive breast cancer

Results from Roche's trastuzumab emtansine Phase III trial on HER2-positive breast cancer

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

Hoffman La Roche, Mylan enter settlement and license agreement for XELODA Tablets

Hoffman La Roche, Mylan enter settlement and license agreement for XELODA Tablets

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Study finds link between genetic variation and cetuximab rectal cancer therapy

Study finds link between genetic variation and cetuximab rectal cancer therapy

Medicare to cover 2 expensive cancer drugs

Medicare to cover 2 expensive cancer drugs

Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO

Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting